G6PD rs5030868: Understanding the Mediterranean Variant
The rs5030868 variant is a well-studied genetic change in the G6PD gene, commonly referred to as the G6PD Mediterranean allele. It is associated with reduced activity of the G6PD enzyme, which can increase susceptibility to hemolytic anemia when triggered by certain medications, infections, or fava beans.
What each genotype means
Normal enzyme activity
This genotype represents the reference sequence for the G6PD gene, often referred to as the G6PD B allele. Individuals with this genotype typically possess normal glucose-6-phosphate dehydrogenase enzyme activity and are not considered at increased risk for G6PD deficiency-related hemolysis based on this specific variant.
This is the most common genotype globally, representing the standard functional form of the G6PD enzyme.
Reduced enzyme activity
This heterozygous genotype is often found in females, who carry one reference allele and one 'Mediterranean' variant allele. Depending on the pattern of X-chromosome inactivation, these individuals may have a mosaic of normal and deficient red blood cells, which can lead to variable sensitivity to oxidative stress or certain medications. Please discuss your medication management and potential triggers with your clinician or pharmacist.
This genotype is observed in populations where the Mediterranean variant is prevalent, particularly in regions surrounding the Mediterranean Sea and parts of the Middle East.
Deficient enzyme activity
This genotype, often referred to as the G6PD Mediterranean variant, is associated with significantly reduced or absent G6PD enzyme activity. Individuals with this profile are at an increased risk for acute hemolytic anemia when exposed to certain oxidative triggers, such as specific medications or fava beans. It is essential to consult with your healthcare provider or pharmacist regarding safe medication choices and to avoid known triggers.
This genotype is most frequently identified in individuals of Mediterranean, Middle Eastern, and some Asian ancestries.
What is rs5030868 and Where is it Located?
The rs5030868 variant is a single nucleotide polymorphism (SNP) located within the G6PD gene on the X chromosome. In scientific literature, this specific change is often identified as c.653C>T, which results in an amino acid substitution known as p.Ser218Phe (or S218F). Because the G6PD gene is located on the X chromosome, the inheritance pattern is X-linked. This means that males, who have only one X chromosome, will express the phenotype associated with their single copy of the gene. Females, having two X chromosomes, may be homozygous or heterozygous for the variant. The variant is widely recognized in clinical genetics as the 'Mediterranean' allele, a designation reflecting its historical identification and prevalence in populations around the Mediterranean basin.
The Role of the G6PD Gene
The G6PD gene provides instructions for making the glucose-6-phosphate dehydrogenase enzyme. This enzyme plays a critical role in red blood cells by protecting them from oxidative damage. It helps produce a molecule called NADPH, which maintains levels of glutathione, an antioxidant that neutralizes harmful reactive oxygen species. When G6PD activity is significantly reduced, red blood cells become vulnerable to oxidative stress. Under normal conditions, many individuals with G6PD deficiency remain asymptomatic. However, when exposed to specific triggers—such as certain medications, fava beans, or severe infections—the red blood cells may break down prematurely, a process known as hemolysis. This can lead to acute hemolytic anemia, characterized by fatigue, jaundice, and dark urine.
Research and Clinical Significance
Research into rs5030868 has established it as a clinically significant variant associated with G6PD deficiency. Studies have linked this variant to varying levels of residual enzyme activity, often placing it in categories that predispose individuals to hemolytic episodes. While the evidence for its impact on enzyme function is robust, the clinical manifestation can be highly variable between individuals. Some research has explored potential associations with drug sensitivity, such as responses to certain antidiabetic medications like glibenclamide, though the significance of these findings often requires further validation. It is important to note that G6PD deficiency is a complex condition influenced by both genetic and environmental factors. Clinicians often use enzyme activity assays alongside genetic testing to assess an individual's risk profile.
Population Frequency
The frequency of the rs5030868 variant is highly variable across different global populations. It is most commonly observed in individuals of Mediterranean, Middle Eastern, and some Asian descent. Because it is an X-linked trait, the prevalence of the deficiency phenotype is typically higher in males than in females. In regions where malaria was historically endemic, certain G6PD variants have been maintained at higher frequencies due to a potential protective effect against severe malaria, though this evolutionary advantage comes with the trade-off of increased susceptibility to hemolytic triggers.
Managing Genetic Information
Understanding your genetic status regarding rs5030868 can be a useful tool for personal health management, but it should not be used for self-diagnosis. If you are aware that you or a family member carries this variant, it is essential to discuss this information with a healthcare provider or a clinical geneticist. They can provide context on what this means for your specific health history and advise on potential triggers to avoid. You should never make changes to prescribed medications or dietary habits based solely on genetic test results without professional medical guidance. A pharmacist or physician can help you identify medications that may pose a risk for individuals with G6PD deficiency and suggest safer alternatives if necessary.
How common is this variant?
The rs5030868 variant is highly variable by ethnicity, with significant prevalence in Mediterranean and Middle Eastern populations.
Frequently asked questions
What is G6PD deficiency?
G6PD deficiency is a genetic condition where the body does not produce enough of the G6PD enzyme. This enzyme protects red blood cells from damage, and its absence can lead to hemolytic anemia when triggered by certain substances.
Can I be tested for rs5030868?
Yes, this variant can be identified through genetic testing. If you are concerned about G6PD deficiency, consult your doctor about whether a genetic test or an enzyme activity blood test is appropriate for you.
What should I avoid if I have G6PD deficiency?
Individuals with G6PD deficiency are often advised to avoid specific triggers, such as fava beans and certain medications known to cause hemolysis. Always consult your pharmacist or doctor for a personalized list of substances to avoid.
Is G6PD deficiency dangerous?
For most people, G6PD deficiency is manageable and does not cause daily symptoms. However, it can lead to serious health issues if the individual is exposed to specific triggers, making awareness of one's status important.
Sources & further reading
Educational information only, last refreshed 10/1/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs5030868?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in G6PD
Known as the G6PD A+ variant (p.Asn126Asp), this polymorphism is common in African populations. While it does not cause G6PD deficiency on its own, it is a component of the G6PD A- haplotype, which is associated with reduced enzyme stability and clinical deficiency.
Coding variant associated with G6PD deficiency and susceptibility to acute hemolytic anemia upon oxidative stress or exposure to hemolytic drugs.
Causes the A- variant of G6PD deficiency, common in African populations.
Causes G6PD deficiency and favism risk in Mediterranean populations.
This variant is associated with G6PD deficiency, which can lead to hemolytic anemia upon exposure to certain medications or fava beans.
This variant is associated with G6PD deficiency, which can lead to hemolytic anemia when exposed to certain medications or stressors.